期刊
NEW GENETICS AND SOCIETY
卷 32, 期 4, 页码 405-428出版社
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/14636778.2013.852010
关键词
genetic testing; genomic medicine; oncology; actionability; personalized medicine
类别
资金
- Canadian Institutes for Health Research (CIHR) [MOP-93553]
- Fonds Quebecois de la Recherche sur la Societe et la Culture (FQRSC) [SE-124896, SE-164195]
- Social Sciences and Humanities Research Council of Canada (SSHRC) [410-2011-2290]
- Genome Quebec
This article explores commercial, academic, and national initiatives aimed at using sequencing technologies to generate actionable genomic results that can be applied to the clinical management of oncology patients. We argue that the term actionable is not merely a buzzword, but signals the emergence of a distinctive sociotechnical regime of genomic medicine in oncology. Unlike other regimes of genomic medicine that are organized around assessing and managing inherited risk for developing cancer (e.g. BRCA testing), actionable regimes aim to generate predictive relationships between genetic information and drug therapies, thereby generating new kinds of clinical actions. We explore how these genomic results are made actionable by articulating them with existing clinical routines, clinical trials, regulatory regimes, and health care systems; and in turn, how clinical sequencing programs have begun to reconfigure knowledge and practices in oncology. Actionability regimes confirm the emergence of bio-clinical decision-making in oncology, whereby the articulation of molecular hypotheses and experimental therapeutics become central to patient care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据